TerminatedNCT01129674

A Long-Term, Open-Label, Study on Schizophrenia

Medication studyAges 18–65Multiple countries

The study in practice

Understand this study

Who could participate?

This study is for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria apply.

Listed locations: Little Rock and 80 more locationsSee all locations and recruitment
Study phase: Phase 2 / Phase 3

What to know before participating

A point to clarify

This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?

Study clarity

Things to check before joining

Study start dateJune 2010

Recruitment status: Terminated
Enrollment listed in the registry: 560
Sponsor: Denovo Biopharma LLC
Sponsor type: Biotech company
Study type: Drug
Intervention type: Medication / drug
Study phase: Phase 2, Phase 3
Locations: United States, Croatia, Japan, ...
Age range: From 18 Years to 65 Years
Official registry ID: NCT01129674
Official title: Show the full official title
A Long-Term, Open-Label, Multicenter Study of LY2140023 Compared to Atypical Antipsychotic Standard of Care in Patients With DSM-IV-TR Schizophrenia

Questions about this study?

The HopeStage team will email you.

Recruitment & locations

Terminated

Little Rock, United States · Escondido, United States · Garden Grove, United States

79 more locations

Long Beach, United States
National City, United States
Oakland, United States
Oceanside, United States
Paramount, United States
Pasadena, United States
San Diego, United States
Sherman Oaks, United States
Torrance, United States
Washington D.C., United States
Fort Lauderdale, United States
Hollywood, United States
Kissimmee, United States
Maitland, United States
University Park, United States
Atlanta, United States
Chicago, United States
Hoffman Estates, United States
Indianapolis, United States
Wichita, United States
Lake Charles, United States
Shreveport, United States
Flowood, United States
Creve Coeur, United States
Marlton, United States
Buffalo, United States
Cedarhurst, United States
Holliswood, United States
New York, United States
Rochester, United States
Cincinnati, United States
Dayton, United States
Philadelphia, United States
Austin, United States
Dallas, United States
DeSoto, United States
Houston, United States
Richmond, United States
Roanoke, United States
Zagreb, Croatia
Aichi, Japan
Kanagawa, Japan
Kumamoto, Japan
Kyoto, Japan
Nagano, Japan
Nagasaki, Japan
Nara, Japan
Osaka, Japan
Saga, Japan
Tokyo, Japan
Toyama, Japan
Guadalajara, Mexico
Monterrey, Mexico
Ponce, Puerto Rico
San Juan, Puerto Rico
Khot'kovo, Russia
Lipetsk, Russia
Moscow, Russia
Nizhny Novgorod, Russia
Saint Petersburg, Russia
Samara, Russia
Saratov, Russia
Tomsk, Russia
Voronezh, Russia
Yaroslavl, Russia
Goyang-si, South Korea
Incheon, South Korea
Naju, South Korea
Seoul, South Korea
Suwon, South Korea
Yŏngin, South Korea
Changhua, Taiwan
Neihu District, Taiwan
Taipei, Taiwan
Donetsk, Ukraine
Kherson, Ukraine
Kiev, Ukraine
Vinnytsia, Ukraine
Russia

A listed location does not confirm current availability.

FAQ

Questions about this study

Who is behind this study?

The study sponsor is Denovo Biopharma LLC.

Does this study involve medication?

Yes. The study involves medication, including LY2140023, Olanzapine, Aripiprazole, Risperidone and Quetiapine.

Who can participate?

This study is for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria apply.

Is this study still recruiting?

The registry lists this study as terminated.

Explore other studies

Want to find a study that may fit you better?

Answer a few simple questions to explore HopeStage studies by condition, country, and situation.

Find a study that may fit me